Mather Group, Llc. Catalyst Pharmaceuticals, Inc. Transaction History
Mather Group, Llc.
- $8.17 Billion
- Q2 2024
A detailed history of Mather Group, Llc. transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Mather Group, Llc. holds 465 shares of CPRX stock, worth $9,095. This represents 0.0% of its overall portfolio holdings.
Number of Shares
465Holding current value
$9,095% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CPRX
# of Institutions
285Shares Held
96.6MCall Options Held
29.2KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$366 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY9.13MShares$179 Million2.97% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.1MShares$158 Million0.0% of portfolio
-
State Street Corp Boston, MA6.03MShares$118 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3MShares$58.7 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.01B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...